When considering the design of a nanocarrier, several important factors

should be addressed. An ideal delivery system should be composed of biocompatible and biodegradable materials, reproducibly assemble into the desired size range, encapsulate a wide range of drugs and drug classes, maintain particle size in biological media, have the ability to attach cell-specific targeting groups, and release the therapeutic Inhibitors,research,lifescience,medical at the site of disease. Polymer micelles have received much attention over the past thirty years as drug delivery vehicle [5–11]. In traditional GDC-0449 molecular weight micelle systems, however, there are no mechanisms in place to keep the micelle intact when it is diluted in the bloodstream, where it is below the critical micelle concentration and interacts with surfactant proteins within the blood. Thus, stability Inhibitors,research,lifescience,medical of nanocarriers in biological media remains an issue that needs to be addressed [12]. Some have utilized the approach of chemically conjugating the active drug to Inhibitors,research,lifescience,medical a polymer to potentially

improve stability. However, this “prodrug” approach is dependent on enzymatic or chemical cleavage of the bond to release the active drug [13–15]. In an attempt to add stability to the micelle, various types of micelles have been developed whereby either the core or shell of the micelle has incorporated crosslinking chemistries, thereby imparting stability at low micelle concentrations [16–22]. However, in Inhibitors,research,lifescience,medical many cases, crosslinking is achieved utilizing covalent bonding within the micelle, which does not lend itself to tunable drug release. In addition, in some crosslinked

micelles, the crosslinks are physically located with the drug in the core of the micelle, which may interfere Inhibitors,research,lifescience,medical with pharmaceutical drug action or drug release from the micelle. This paper describes a polymer micelle drug delivery system (IVECT) that has effectively addressed the limitations of traditional polymer micelles, by forming micelles that are stable in biological environments. The IVECT triblock copolymer consists of poly(ethylene glycol)-b-poly(aspartic acid)-b-poly(D-leucine-co-tyrosine). The leucine/tyrosine core why unit in this polymer is able to encapsulate a wide variety of hydrophobic molecules, which is enhanced by the use of both D and L stereoisomers. The poly(aspartic acid) block was designed to participate in a metal-acetate crosslinking reaction that effectively stabilized drugs inside the core of the micelle and also mediates pH-dependent release of the drug. In this paper, a polymer micelle is described that is composed of biocompatible materials, has the versatility to encapsulate a wide range of therapeutic payloads, is stable to dilution within the blood stream, and has a tunable, highly sensitive, and reversible stabilization mechanism.